Corona Remedies vs Pfizer: Share Price, Valuation and Results Compared

Corona Remedies Limited (NSE: CORONA) and Pfizer Ltd. (NSE: PFIZER) are both listed in the Pharmaceuticals industry. Corona Remedies has a market capitalisation of ₹14,481 Cr and Pfizer ₹17,811 Cr, as of 16 Nov 2026. Their P/E ratios are 77.6 and 24.5 respectively. Return on equity is 24.79% for Corona Remedies and 17.16% for Pfizer.

Corona Remedies vs Pfizer — Key Figures

MetricCorona RemediesPfizer
NSE SymbolCORONAPFIZER
BSE Code544644500680
Share Price₹2,335.00₹3,857.00
Market Cap₹14,481 Cr₹17,811 Cr
P/E Ratio77.624.5
Return on Equity24.79%17.16%
Return on Assets14.99%10.77%
Dividend Yield0.43%1.94%
Beta (1Y)0.080.26
1-Year Price Change—-24.2%
3-Month Price Change+10.2%-22.9%
52-Week Range₹1,336.60 – ₹2,719.30₹3,589.00 – ₹5,257.00
Latest QuarterQ2 FY27Q2 FY27
Quarterly Revenue₹441 Cr₹727 Cr
Quarterly Net Profit₹60 Cr₹313 Cr
Net Margin13.7%43.1%
EPS (Basic, Quarter)₹9.86₹68.47
Results Basisconsolidatedstandalone
HeadquartersAhmedabad, GujaratMumbai, Maharashtra

The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.

About the Companies

Corona Remedies Limited

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

Pfizer Ltd.

Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was…

Frequently Asked Questions

Which is larger by market cap, Corona Remedies or Pfizer?

Pfizer has a market capitalisation of ₹17,811 Cr, against ₹14,481 Cr for Corona Remedies as of 16 Nov 2026, about 1.2 times the size by market cap.

What is the P/E ratio of Corona Remedies and Pfizer?

Corona Remedies has a P/E of 77.6 and Pfizer a P/E of 24.5 as of 16 Nov 2026.

What is the return on equity of Corona Remedies and Pfizer?

Corona Remedies has a return on equity of 24.79% and Pfizer 17.16%.

What were the latest quarterly results of Corona Remedies and Pfizer?

Corona Remedies reported revenue of ₹441 Cr and net profit of ₹60 Cr for Q2 FY27. Pfizer reported revenue of ₹727 Cr and net profit of ₹313 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.

Which industry are Corona Remedies and Pfizer in?

Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.

Is this comparison a recommendation to buy or sell Corona Remedies or Pfizer?

No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.

More Comparisons

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.